TD Cowen Remains Bullish on Amicus Therapeutics (FOLD) With a $20 PT
Doctors in a lab coat attending to a patient receiving enzyme replacement therapies.
The analyst based the rating on the company's future growth potential and strategic positioning, stating that Amicus Therapeutics, Inc. (NASDAQ:FOLD) has maintained a positive outlook for GAAP profitability in H2 2025.
This trend emerged despite the Q1 revenue misses for both PomOp and Galafold, which were affected by higher UK VPAG rebates. Baral thus reasoned that these trends suggest confidence in the company's operations and its ability to manage costs and drive future profitability.
Another factor supporting the analyst's positive rating is Amicus Therapeutics, Inc.'s (NASDAQ:FOLD) pipeline expansion, especially with the in-licensing of DMX-200 for FSGS. This highlights the company's commitment to boosting its long-term growth prospects and expanding its product offerings, according to Baral.
Amicus Therapeutics, Inc. (NASDAQ:FOLD) discovers, develops, and delivers medicines to treat metabolic diseases. Its product portfolio includes the first and only approved oral precision medicine to treat Fabry disease, a clinical-stage treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio.
While we acknowledge the potential of FOLD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
Disclosure: None. This article is originally published at Insider Monkey.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
17 minutes ago
- Yahoo
Melius Raises Apple (AAPL) PT to $260, Cites Upcoming iPhone Cycles
Apple Inc. (NASDAQ:AAPL) is one of the 10 AI Stocks Making Waves on Wall Street. On August 8, Melius analyst Ben Reitzes raised the price target on the stock to $260.00 (from $240.00) while maintaining a Buy rating. The firm is optimistic about the upcoming iPhone product cycles. It also believes that Siri AI concerns are overblown. 'Apple's stock has reacted nicely to tariff news, but we see focus starting to move toward new products and systematic increases in value for iPhones that drives growth for the next 3+ years. We raise our FY26 EPS estimate 12 cents due to higher gross margins and modestly raise FY27 EPS. Our target adjusts to $260, and we think concerns about the Siri delay are overblown since Apple isn't losing share. Reiterate Buy.' Melius is optimistic that a new iPhone product cycle starting in September will likely improve product mix. This will in turn boost growth in high single digits during some quarters. 'We are optimistic that our iPhone estimates can be conservative based on new product cycles that include an 'iPhone Air' this September, a foldable model in FY26 and the iPhone 20 line-up in late FY27 (20th year anniversary models). Luckily for Apple, its iPhone base doesn't seem to care about the Siri/AI delays, and we see no evidence of real switching.' With more iPhone catalysts, expensive models such as foldables will likely help increase total revenue. 'The iPhone has more catalysts in 2026 with the introduction of a foldable model that should be priced around $2,000 and then the iPhone 20 ('20th anniversary') cycle in 2027. As foldables 'mix in' there can be big revenue growth even on flat units.' Apple is a technology company known for its consumer electronics, software, and services. While we acknowledge the potential of AAPL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and Disclosure: None. Sign in to access your portfolio
Yahoo
17 minutes ago
- Yahoo
Datadog (DDOG) Price Target Raised to $147 on Strong Born-in-AI Growth
Datadog, Inc. (NASDAQ:DDOG) is one of the 10 AI Stocks Making Waves on Wall Street. On August 8, Bernstein SocGen Group analyst Peter Weed raised the price target on the stock to $147.00 (from $145.00) while maintaining an Outperform rating. According to the firm, Datadog's Q2 on first blush was a blowout, with the beat reflecting another outperformance by their Born-in-AI cohort. 'Datadog's Q2'25 on first blush was a blowout, with the largest $ beat vs. midpoint guide ever, even besting the frothy Q4'21 earnings at the height of COVID cloud consumption mania. Even on a % basis it was the largest beat since 2022. " Datadog, Inc. (NASDAQ:DDOG) offers a cloud-based SaaS platform for monitoring and analytics, specializing in cloud computing and AI-powered cybersecurity products. While we acknowledge the potential of DDOG as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
17 minutes ago
- Yahoo
KeyBanc Reaffirms Overweight on Constellation (CEG), Eyes Year-End Deal
Constellation Energy Corporation (NASDAQ:CEG) is one of the 10 AI Stocks Making Waves on Wall Street. On August 8, KeyBanc analyst Sophie Karp raised the price target on the stock to $359.00 (from $337.00) while maintaining an Overweight rating. The firm noted how Constellation reported its second-quarter results slightly ahead of consensus expectations, reiterating both its 2025 and long-term guidance. However, shares were down amid no deals announcement. 'Shares were slightly down (-0.4% vs. UTY +1.0%) as the Company did not announce a deal, but we expect one to be announced by yearend as the Company highlighted two, with one specifically in the late stages.' Keybanc is optimistic about upcoming deals considering how Constellation remains well-positioned to capitalize on the expanding data economy and its 'intrinsically appreciating generation fleet.' Recent PJM results and the company's long-term power purchase agreement with Meta supports this thesis. The company also talked about other near-term catalysts. 'Other NT catalysts include FERC resolution with resulting regulatory clarity and the closing of the Calpine deal. That said, we believe the scarcity value of CEG's assets will continue to put upward pressure on shares as more deals are announced and expect buybacks to provide support for the share price. Reiterate OW rating, raise PT to $359.' Constellation Energy Corporation (NASDAQ:CEG) is an energy provider specializing in clean, carbon-free energy solutions. While we acknowledge the potential of CEG as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and Disclosure: None.
